Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 145Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Lymphoma, Large B-Cell, Diffuse 89Leukemia 74Lymphoma, Non-Hodgkin 60Lymphoma, Follicular 47Burkitt Lymphoma 46Lymphoma, Mantle-Cell 43Hodgkin Disease 31Neuroblastoma 30Central Nervous System Neoplasms 29Sarcoma 24Lymphoma, Large-Cell, Immunoblastic 23Lymphoma, Large-Cell, Anaplastic 21Multiple Myeloma 19Leukemia, Lymphocytic, Chronic, B-Cell 16Lymphoma, B-Cell, Marginal Zone 15HIV Infections 15Brain Neoplasms 15Medulloblastoma 11Dendritic Cell Sarcoma, Interdigitating 11Astrocytoma 11Acquired Immunodeficiency Syndrome 11Wilms Tumor 10Rhabdomyosarcoma 10Lymphoma, T-Cell, Peripheral 10Lymphoma, B-Cell 10Recurrence 9Oligodendroglioma 9Neuroectodermal Tumors, Primitive, Peripheral 9

Interventions

trametinib 1dabrafenib 1Vincristine 1Irinotecan 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ganglioneuroma × Vincristine × Clear all
NCT02684058 2023-12-13

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Novartis

Phase 2 Completed
151 enrolled 45 charts 1 FDA
CNS

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Oligodendroglioma, Ganglioglioma, Neurocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡